Member Info for elrico

Does anyone else have a feeling SOH is trying to offer us a clue with todays Proactive interview? SOH usually comments on updates, etc. This seems to have a specific agenda centred around big pharmas interest in LP-LDL. No I have not asked as this would be futile and make me luck a right chump ;)

Boyzee - I don't see an issue with biomes future and certainly not with OPTI's OTC products because they are already regulated (if you like) via "generally regarded as safe" (GRAS). Pharma route is more regulated because they are not using natural products but man-made synthetics and there is a need to test before widespread use. It's a very simplified explanation.

Comment from SOH on an unrelated topic I had put to me for SOH related to antibiotics. "We can�t create new antibiotics but their is growing evidence to suggest that by modifying the microbiome you can increase the effectiveness of a range of therapeutics. In the last few months the level of interest in this area has increased as pharma companies have recognised the potential but also as a result of some high profile failings in drug development." "We do not intend to enter the pharma market but I have built the company using pharma platforms and covered medical applications in our patent applications so we can partner or license out our technology if the opportunity arises." Clearly, OPTI have IP ready for pharmaceutical platforms. This is a huge plus for the likes of pharma seeking new drugs and or increase the life of existing drugs because most of the work has been conducted for them. It would save them �ms in R&D and time and most likely a much quicker route to market. What I don't understand at this stage, is how an OTC GRAS scientifically proven products' route to becoming a key ingredient in a pharmaceutical products? It would be really useful to know the key stages a pharma products route to markets (assuming all is successful) from initial R&D right through to phases 1-3 to final approval from regulatory bodies. Time consuming and expensive for sure!

THE BEAUTY OF BIO WE KNOW PROBIOTICS CAN HELP YOUR DIGESTION BUT WHAT CAN THEY DO FOR YOUR SKIN CLAIRE COLEMAN INVESTIGATES With the hottest health-food books of the year invariably featuring the word "gut" or "microbiome", we've become quite au fait with probiotics and looking after the "good bacteria" in our stomachs. The latest figures suggest that whether we're popping a supplement after a course of antibiotics, replacing our regular yoghurt with Activia, or even making our own kefir and kimchi, we're more pro-probiotics (sorry) than we've ever been before. But what about "good" bacteria in your skincare? Could the technology that gives us a healthy gut also be the answer to our dreams of a clear, glowing complexion? Brands such as Aurelia Probiotic Skincare and Gallinee, with its "skincare for the microbiome", think so. The mainstream brand Clinique has also jumped on the band- wagon, with its Redness Solution range that contains "probiotic technology", while Vichy, Niod and La Roche-Posay are all using probiotic and prebiotic ingredients. Skin conditions such as rosacea and acne seem most likely to benefit from probiotic technology, but there is increasing evidence that the secret to anti-ageing could, in part, be down to keeping the bacteria on your skin happy. Recent research shows that the number and type of bacteria in the microbiome of healthy skin is different to that of skin affected by acne, eczema, psoriasis and other types of inflammation. One theory is that if we tinker with the microbiome, making it more like that of healthy skin, we could get rid of certain skin conditions and even slow the rate at which it ages, as that is related to inflammation, too. Only, of course, it's not that simple. "Keeping bacteria alive in a cosmetic cream is hard," says Dr. Catherine O'Neil, senior lecturer in clinical biochemistry in the dermatological sciences research group at the University of Manchester. "Even if it weren't, we don't know if it would be safe to apply live bacteria to potentially compromised skin." Instead, what most of these skincare companies are doing is creating extracts that have the same effects as live bacteria. "The microbiome changes the skin because molecules in the bacteria send messages to the body. But these signaling molecules can still be present in a 'dead' extract," O'Neil says. "We have found an extract that can strengthen the skinbarrier, exclude pathogens and heal skin in the same way the original bacteria can." Her findings will form the basis of products created by the SkinBio Therapeutics brand in the future. According to Elisa Simonpietri, head of science at Vichy, that's exactly how one of the strengthening, hydrating ingredients in its Slow Age range works. It is made by fermenting a type of bacterium called Bifidobacterium longum and, though no longer live, "it still has the

Pitiful volume, nothing to worry about. The commercial agreement are winging there way in good time.

Corespreads and ETX - dropped IG over 12 months ago. Core has all my OPTI SB positions, they have been close only for almost 18 months. ETX wouldn't take a long position for a similar period until around April but they wanted 100% margin while my Core was 10%. Core right now will not take a bet either way - close only, so I am not trading OPTI, just standing firm on what I have.

More like SB firm(s) cynical attempt to get long positions out. Three SB providers I have used are all close only, you can't go long and if you can it 100% margin. I'm not saying I am 100% correct here, but it makes sense from people I chat with. I don't care either way, because my SB is fully funded all the way down to 40p. I won't be shook out of a position I can't get back in on the same 10% margin.

On commercial strategy. I forgot to post it yesterday. https://goo.gl/kdka8s

Odd that nobody agree with either you or TW. This so called "non news" was released by SOH as a part tool to keep lurking companies updated. It's a marketing tool which costs peanuts. SOH take on reach RNS. Clue is in the title "reach." 1.The fact that Sacco have appointed a product Manager at significant financial cost to support entry to the US probiotic market and extend the product opportunity into dairy. Sacco are one of the worlds largest probiotic manufacturers and this reflects the confidence they have in the product i.e a major manufacturer is paying to promote and sell our products in the US. This investment is expected to be in the region of over �500K and provides investors with an update to our RNS in August where we announced the Sacco deal and indicated a commitment from them to support the funding of further developments to expand the commercialisation of LPLDL� into new markets. This is a big commitment by a partner to access a big market. 2. The incorporation of SlimBiome into cereal products with one of the major suppliers to cereal manufacturers such as Kelloggs, Nestle, General Mills etc in the US. Investors who read our interims will remember that we stated that we see the deal with Tata as the first of a number of deals in international markets. Given we have a B2B strategy then central to any deal in international markets is a relationship with a manufacturer who can provide SlimBiome in different formats for consumer companies like Kelloggs, General Mills etc. This announcement builds on our interims and reports a new technical innovation which extends the opportunities for SlimBiome to the US in the substantive health and well bing sectors. At OptiBiotix we try to inform investors of progress, or otherwise, so they can make their investment decisions based on a reliable source. Some announcements will announce commercials deals whilst others provide a pointer to the direction of the company and the progress it is making. This RNS REACH was announced to inform investors of the launch of products with partners into the US markets. We feel this information is of value to investors, particularly given the scale of the opportunity offered by the US market. This was signalled in our interims and supported by our recent FDA registration, itself a significant milestone for the company. Clearly we would not have expanded our reach unless we had confidence in our products. This confidence has also been shown by our partners who have provided us with exhibition space, appointed new staff, and developed products at their own cost. This is highly unusual in this market and reflects the confidence these partners have in OptiBiotix. We believe this was worthwhile sharing with investors.

I would imagine cholesterol and or hypertension issues cannot be ignored. Similarly, I hate taking meds of any prescription. If nothing else, you will have first experience of OPTI's claim and assured you (assumed ) of the validity of your investment decision based on scientific grounds, if not market acceptance.....just yet, as some would argue blindly.

It wasn't me that bought them. Parob posted the links on the other thread. http://tinyurl.com/yc5mxjnu (Apo-Rot U.K. Site) OR EBAY UK Site http://www.ebay.co.uk/itm/Lactobact-LDL-CONTROL-90St-PZN-13502016-/132297372469?epid=2152009710&hash=item1ecd89b335:g:u84AAOSwZs1Zf0To

Quite right to - Korg. The Supply Side West tradeshow brings together more than 15,000 ingredient buyers and suppliers from the supplement, beverage, functional food, personal care and sports nutrition industries and is viewed as one of the world's leading trade fairs for the food and drinks industry. Read it again! OptiBiotix will co-exhibit with Sacco and will present new product concepts, as well as launching existing products containing its cholesterol reducing strain (LP(LDL) (R)) at the show, including:- -- CholBiome(R): a proprietary formulation containing LP(LDL) (R) to reduce cholesterol levels and blood pressure; and -- CardioBiome(R): a proprietary formulation containing LP(LDL) (R) to reduce a wide range of cardiovascular disease factors and improve long term heart health. The US launch of LP(LDL) (R), CholBiome(R) and CardioBiome(R) at Supply Side West is the first of a number of commercial steps taken to supply LP(LDL) (R) to food, beverage, consumer healthcare and pharmaceutical partners to be incorporated into final formulations and presentations for distribution and sale into the US market. The US is one of the largest and fastest-growing probiotic markets in the world, with supplements alone accounting for US$2.06bn sales, with a projected 55% growth to US$3.3bn by 2021. Discussions continue to progress with corporate partners for the manufacture and distribution of products containing LP(LDL) (R) in the European, Asian and other international markets. Still don't get it Korg? Read it again! Any questions for the teachers on this BB? I'm sure there are one or two that will be very pleased to help you. ;)

nicktopten4 Oct '17 - 16:21 - 27686 of 27750 25 UPDATE: Im half way through the course of Lactobact LPLDL. No side effects at all. My blood pressure at start (six weeks ago) was 140 over 98. It is now 122 over 81. I was not expecting any noticeable reduction as LPLDL is primarily for reduction in cholesterol. I am gobsmacked!! My blood pressure has not been in this range since my twenties and Im mid fifties now. Indeed, last year I was prescribed Ace Inhibitors to reduce blood pressure, but the best they could do was 130 over 95 (diastolic still quite high) so I gave up taking them. As I mentioned previously my cholesterol level was 5.5 at start and I will have another blood test at end of course and let you know outcome. All good here !! SOH reaction We are confident from our laboratory and human studies that we have a safe and effective product and are pleased that we have been able to help an investor reduce his high blood pressure without the use of medications like the Ace inhibitors or statins and their associated side effects. Our data shows a similar group effect on blood pressure and cholesterol across a much wider population group (young/old; male/female; high/medium cholesterol etc) and of course in much higher population numbers. Our data shows the higher the blood pressure or cholesterol the greater the effect so the benefits are greatest in those most in need. This product is just a single example of a range of products we are launching to reduce blood pressure, cholesterol, cardiovascular risk, and more general products to promote healthy ageing. We are launching these products in capsule, tablet, and satchet format with partners in Europe, Asia, and the US, and hope to be able to offer the clear benefits these safe and natural products produce to consumers in the UK either via online channels and/or retail stores later this year/ at the start of 2018. It is increasingly being recognised that these next generation natural products are the future of modern healthcare and you will see increasing evidence for the widespread use of these products over the forthcoming months and years. We are pleased, and hopefully investors are excited, that OptiBiotix is leading this revolution in healthcare and feel that as the evidence base and usage of these products grow we will be able to build a �200-600m company in the years ahead. I believe OptiBiotix is unique in that it has gone through a pharmaceutical like development process to identify, develop, and validate the safety and efficacy of natural microbiome modulating products based on strong science, independent humans studies, and world key opinion leader support. We believe this offers investors a great investment as well as the opportunity to shape the future of modern healthcare. (Please feel free to post and share with others). Best Wishes, Stephen OHara

TW and other investors have missed a couple of key points :- 1. The fact that Sacco have appointed a product Manager at significant financial cost to support entry to the US probiotic market and extend the product opportunity into dairy. Sacco are one of the worlds largest probiotic manufacturers and this reflects the confidence they have in the product i.e a major manufacturer is paying to promote and sell our products in the US. This investment is expected to be in the region of over �500K and provides investors with an update to our RNS in August where we announced the Sacco deal and indicated a commitment from them to support the funding of further developments to expand the commercialisation of LPLDL� into new markets. This is a big commitment by a partner to access a big market. 2. The incorporation of SlimBiome into cereal products with one of the major suppliers to cereal manufacturers such as Kelloggs, Nestle, General Mills etc in the US. Investors who read our interims will remember that we stated that we see the deal with Tata as the first of a number of deals in international markets. Given we have a B2B strategy then central to any deal in international markets is a relationship with a manufacturer who can provide SlimBiome in different formats for consumer companies like Kelloggs, General Mills etc. This announcement builds on our interims and reports a new technical innovation which extends the opportunities for SlimBiome to the US in the substantive health and well bing sectors. At OptiBiotix we try to inform investors of progress, or otherwise, so they can make their investment decisions based on a reliable source. Some announcements will announce commercials deals whilst others provide a pointer to the direction of the company and the progress it is making. This RNS REACH was announced to inform investors of the launch of products with partners into the US markets. We feel this information is of value to investors, particularly given the scale of the opportunity offered by the US market. This was signalled in our interims and supported by our recent FDA registration, itself a significant milestone for the company. Clearly we would not have expanded our reach unless we had confidence in our products. This confidence has also been shown by our partners who have provided us with exhibition space, appointed new staff, and developed products at their own cost. This is highly unusual in this market and reflects the confidence these partners have in OptiBiotix. We believe this was worthwhile sharing with investors. We will continue to inform investors of how we are building the company across all platforms and territories. As I have often repeated we will not speculate on the timings or numbers of specific deals with partners as we respect the confidentiality and support these partners provide. We believe this approach is more valuable in the longer term for investors.

Korg - Seriously dude, you need to read up, digest before proposing a case against something you clearly DO NOT UNDERSTAND. The rudimentary basics are easily available. I have no issue interacting with you - you always come off the worse, not me, because unlike you, I actually know what I am talking about and IF I'm unsure, I ask the appropriate people so I don't look a fool or knowingly post misinformation. From the company website, no spin from me, just the facts, which seem to escape you. 11 July 2017 OptiBiotix is developing compounds to tackle obesity, high cholesterol and diabetes, announces successful human taste studies in its SweetBiotix® product development programme. The programme has been designed to develop sweet natural healthy fibres, called SweetBiotix®, which are not digested in the human gut, and hence calorie free. The study was carried out by The Flavour and Sensory Science Centre at the University of Reading who tested six customised oligosaccharides developed from high intensity sweeteners which were compared to sucrose. The study used a trained expert panel of ten experienced panellists and showed:- The customised oligosaccharides showed sweetness of between 140X and 223X that of sucrose at equivalent concentrations Customised oligosaccharides derived from Stevia showed a large reduction in bitterness whilst not affecting its sweetness The results of this independent study provide proof of product concept for a natural, low calorie, SweetBiotix®. This is an innovative concept which has the potential to address public health concerns over the impact of sugar on obesity, with the prospect of replacing 'unhealthy' sugars in existing products with low calorie, healthy non-digestible fibres, trademarked as SweetBiotix®. Given the global sweetener market, currently dominated by sugar, is forecast to reach $112bn by 2022 (Mordor Intelligence, 2017), the Company are filing additional patents to add a further layer of protection to the existing intellectual property portfolio to protect their inventions and fully exploit the commercial potential.

There are a number of deals under discussion at various stages of development and these will conclude when all IP, legal, and contractual due diligence has been completed. As I constantly remind investors these don�t run to a set timetable as any sense of panic or requirement to close out quickly can affect the deal structure to the long term detriment of investors. The headline your sent (Chocolate sales plunge by �78m) reflects the industry interest we are receiving in both our functional prebiotics and SweetBiotix with a number of key industry players. There is more to OptiBiotix than SlimBiome and LP-LDL with investors having multiple shots at goal. Biggest chocolate brand sales losers in past year Cadbury Dairy Milk - down �19.9 million (4.2per cent); Galaxy - down �11.4 million (5.2per cent); Malteser's - down �8.9 million (7.6per cent); Aero - down �7.5 million (12.5per cent); Crunchie - down �6.8 million (14.9per cent); Twirl - down �5.7 million (5.8per cent); Snickers - down �5.4 million (6.4per cent); Kinder Surprise - down �5.3 million (7.2per cent); M&M's - down �5.2 million (5.9per cent); Boost - down �3.5 million (10.6per cent); Wispa - down �3.4 million (3.8per cent).

YSF exit in an orderly manner, it is their stated strategy. They are government sponsored to support small businesses. The last tranches they sold (600,000) were placed not sold into the market. The recent sells have been by Ex director David Evans, who is out now. There also a number of wealthy PI, whom seem to trade in and out. Some peeps are not interested in holding long term, pref is short term trading because they think they're good at it. Reality is not in their favour. Their motive is they pay thousand for a trading platform, so the motive is to get use out of it. Good luck to them ;) I dare say one or two panicked on the Las Vegas mass shooting.

You know your onions!

Unfortunately, the world has one too many people that just don't care, are unhelpful, inconsiderate, rude and self centered. I refuse to be. I will help anyone that asks - to a point. I am not attempting to convince anyone to buy OPTI or any company. Irene asked a few questions, I attempted answer. You apparently don't care, so move on!

Irene - Risky picked up on a key points in relation to pharma ready and GRAS, the latter being OTC supplements and raw ingredients to Dairy and food industry. OPTI's LP-LDL for example, is already proved in science, as per Ricky's comments. The pharma route is much more regulated and several years away from a product to to phased trials. In any event, this is not something I would imagine OPTI would embark on due to costs and time. Most likely, OPTI will pick a partner to run with the baton for share of future profits and royalties. In the meantime, said partner would have to pay an upfront license fee.